Novel Therapeutic Strategies for Preventing Recurrent Urinary Tract Infections in Women: A Narrative Review.
- 1Department of Minimally Invasive and Robotic Urology, University Center of Excellence in Urology, Wroclaw Medical University, 50-556 Wroclaw, Poland.
Abstract
Background: It is estimated that approximately 20-30% of women suffer from recurrent urinary tract infections (rUTIs). The disease is primarily bacterial, especially Escherichia coli, making antibiotics the standard treatment. Increasing antibiotic resistance of uropathogens reduces treatment effectiveness. Therefore, non-antibiotic approaches are increasingly being investigated for the management of rUTIs. This narrative review provides a comprehensive overview of currently available and emerging methods of treatment and prevention of rUTIs in women. Methods: This paper employs a narrative review with a structured literature search and synthesizes data from three major databases, including PubMed, Web of Science, and Scopus. The review was conducted in accordance with the Scale for the Assessment of Narrative Review Articles (SANRA) checklist. Scientific articles were searched using the following keywords: 'recurrent urinary tract infections in women', 'antibiotic prophylaxis', 'immunoprophylaxis', 'urinary microbiome'. Results: Observational evidence has reported an association between continuous antibiotic prophylaxis and severe outcomes, including pyelonephritis and septicemia; however, these findings are susceptible to confounding by indication and should not be interpreted as evidence of a causal relationship. Clinical studies suggest that immunomodulatory approaches, such as OM-89 bacterial lysate, next-generation polybacterial mucosal vaccines (e.g., MV140), and oral immunostimulants, have potential to reduce the frequency of rUTI recurrences in women, although the strength and certainty of evidence vary between interventions. Bacteriophage therapy is an emerging and exploratory targeted approach supported by early clinical and experimental evidence, but its efficacy for preventing recurrent uncomplicated UTIs remains uncertain, though rapid development of phage resistance remains a potential limitation. Prophylactic strategies, including Lactobacillus-based probiotics, low-dose estriol, and microbiota transplantation, have shown preliminary or variable results, with limited evidence for rUTI prevention. In particular, findings on vaginal dysbiosis and microbiota modulation should not be interpreted as a direct evidence of rUTI prevention. Conclusions: While antibiotic therapy remains essential, continuous prophylaxis may contribute to antimicrobial resistance and disrupt microbial balance. Therefore, novel therapeutic strategies are still being studied. Several non-antibiotic strategies, including immunoprophylaxis and microbiome modulation, represent potential preventive approaches, whereas bacteriophage therapy and vaginal microbiota transplantation remain exploratory and require further clinical validation. Their preventive efficacy against rUTIs remains unestablished. Moreover, antimicrobial peptides (AMPs), nanotechnology, molecularly targeted therapies, and precision medicine strategies are being investigated. Plant-based therapies may provide benefit, but their clinical efficacy remains to be established. Overall, further clinical studies are needed to confirm the preventive efficacy of these emerging approaches.
Related
- Treatment strategies for postoperative locoregional recurrent esophageal squamous cell carcinoma after curative resection: a narrative review
- Emerging Therapeutic Strategies for Child and Adolescent Obesity: A Narrative Review
- Managing and Preventing Placement‐Based Fatigue in Radiography and Allied Health Students: A Narrative Review
- Fire needle therapy for recurrent skin and soft tissue infections: a case report and literature review
- The efficacy of taurolidine lock solution in preventing catheter-related bloodstream infections in pediatrics: a systematic review and meta-analysis
BibTeX
@article{zawadzki2026novel,
title = {{Novel Therapeutic Strategies for Preventing Recurrent Urinary Tract Infections in Women: A Narrative Review.}},
author = {Dominik Zawadzki and Natalia Libergal and Mikołaj Kisiała and Hanna Gwoździk and Oskar Ratajczyk and Mateusz Hejnowicz and Piotr Misiąg and Łukasz Nowak and Dawid Janczak and Wojciech Krajewski and Tomasz Szydełko and Bartosz Małkiewicz},
journal = {Antibiotics (Basel, Switzerland)},
year = {2026},
month = oct,
doi = {10.3390/antibiotics15101030},
url = {https://europepmc.org/article/MED/42938771},
note = {CC BY},
}
RIS
TY - JOUR
TI - Novel Therapeutic Strategies for Preventing Recurrent Urinary Tract Infections in Women: A Narrative Review.
AU - Dominik Zawadzki
AU - Natalia Libergal
AU - Mikołaj Kisiała
AU - Hanna Gwoździk
AU - Oskar Ratajczyk
AU - Mateusz Hejnowicz
AU - Piotr Misiąg
AU - Łukasz Nowak
AU - Dawid Janczak
AU - Wojciech Krajewski
AU - Tomasz Szydełko
AU - Bartosz Małkiewicz
PY - 2026
DA - 2026/10/16
JO - Antibiotics (Basel, Switzerland)
DO - 10.3390/antibiotics15101030
UR - https://europepmc.org/article/MED/42938771
AB - Background: It is estimated that approximately 20-30% of women suffer from recurrent urinary tract infections (rUTIs). The disease is primarily bacterial, especially Escherichia coli, making antibiotics the standard treatment. Increasing antibiotic resistance of uropathogens reduces treatment effectiveness. Therefore, non-antibiotic approaches are increasingly being investigated for the management of rUTIs. This narrative review provides a comprehensive overview of currently available and emerging methods of treatment and prevention of rUTIs in women. Methods: This paper employs a narrative review with a structured literature search and synthesizes data from three major databases, including PubMed, Web of Science, and Scopus. The review was conducted in accordance with the Scale for the Assessment of Narrative Review Articles (SANRA) checklist. Scientific articles were searched using the following keywords: 'recurrent urinary tract infections in women', 'antibiotic prophylaxis', 'immunoprophylaxis', 'urinary microbiome'. Results: Observational evidence has reported an association between continuous antibiotic prophylaxis and severe outcomes, including pyelonephritis and septicemia; however, these findings are susceptible to confounding by indication and should not be interpreted as evidence of a causal relationship. Clinical studies suggest that immunomodulatory approaches, such as OM-89 bacterial lysate, next-generation polybacterial mucosal vaccines (e.g., MV140), and oral immunostimulants, have potential to reduce the frequency of rUTI recurrences in women, although the strength and certainty of evidence vary between interventions. Bacteriophage therapy is an emerging and exploratory targeted approach supported by early clinical and experimental evidence, but its efficacy for preventing recurrent uncomplicated UTIs remains uncertain, though rapid development of phage resistance remains a potential limitation. Prophylactic strategies, including Lactobacillus-based probiotics, low-dose estriol, and microbiota transplantation, have shown preliminary or variable results, with limited evidence for rUTI prevention. In particular, findings on vaginal dysbiosis and microbiota modulation should not be interpreted as a direct evidence of rUTI prevention. Conclusions: While antibiotic therapy remains essential, continuous prophylaxis may contribute to antimicrobial resistance and disrupt microbial balance. Therefore, novel therapeutic strategies are still being studied. Several non-antibiotic strategies, including immunoprophylaxis and microbiome modulation, represent potential preventive approaches, whereas bacteriophage therapy and vaginal microbiota transplantation remain exploratory and require further clinical validation. Their preventive efficacy against rUTIs remains unestablished. Moreover, antimicrobial peptides (AMPs), nanotechnology, molecularly targeted therapies, and precision medicine strategies are being investigated. Plant-based therapies may provide benefit, but their clinical efficacy remains to be established. Overall, further clinical studies are needed to confirm the preventive efficacy of these emerging approaches.
SN - 2079-6382
ER -